{"id":8467,"date":"2026-10-30T15:48:22","date_gmt":"2026-10-30T07:48:22","guid":{"rendered":"https:\/\/zepbound-japan.com\/?post_type=product&#038;p=8467"},"modified":"2026-10-30T21:40:07","modified_gmt":"2026-10-30T13:40:07","slug":"1793347459","status":"publish","type":"product","link":"https:\/\/zepbound-japan.com\/en\/product\/1793347459\/","title":{"rendered":"Japan's Mounjaro (Tirzepatide), a long-acting GIP\/GLP-1 receptor agonist for lowering cholesterol and weight loss"},"content":{"rendered":"<div class=\"mj-wrap\" style=\"max-width: 760px; margin: 0 auto; padding: 0 12px; color: #1c2328; font-family: 'PingFang TC','Hiragino Sans','Noto Sans TC','Microsoft JhengHei','Noto Sans JP',sans-serif; -webkit-font-smoothing: antialiased; line-height: 1.65; font-size: 15px; box-sizing: border-box;\">\n<style data-rm-block-id=\"block-1\">\n@import url(\"https:\/\/fonts.googleapis.com\/css2?family=Noto+Sans+TC:wght@400;500;600;700&family=Noto+Serif+JP:wght@600;700&display=swap\");<br \/>.mj-wrap *,.mj-wrap *::before,.mj-wrap *::after{box-sizing:border-box}<br \/>.mj-wrap table{width:100%;border-collapse:collapse;font-size:13px;margin:10px 0}<br \/>.mj-wrap th,.mj-wrap td{border:1px solid #e4dfd6;padding:8px 10px;vertical-align:top;text-align:left;white-space:normal;overflow-wrap:anywhere;word-break:break-word}<br \/>.mj-wrap th{background:#f3efe8;color:#1c2328;font-weight:600}<br \/>.mj-wrap img{max-width:100%;height:auto}<br \/>.mj-wrap .mj-specs-wrap{overflow:visible}<br \/>@media (max-width:640px){<br \/>  .mj-sheet-inner{padding:20px 14px 16px !important}<br \/>  .mj-title{font-size:19px !important}<br \/>  .mj-h{font-size:16px !important}<br \/>  .mj-kicker{letter-spacing:.12em !important;font-size:10px !important}<br \/>  .mj-wrap .mj-specs,<br \/>  .mj-wrap .mj-specs tbody,<br \/>  .mj-wrap .mj-specs tr{display:block;width:100%}<br \/>  .mj-wrap .mj-specs th,<br \/>  .mj-wrap .mj-specs td{display:block;width:100%;max-width:100%}<br \/>  .mj-wrap .mj-specs th{padding:12px 12px 2px !important;background:transparent !important;border:0 !important;font-size:12px !important;color:#2c5a52 !important}<br \/>  .mj-wrap .mj-specs td{padding:2px 12px 12px !important;border:0 !important;border-bottom:1px solid #e4dfd6 !important;font-size:13px !important;line-height:1.7 !important}<br \/>  .mj-wrap .mj-specs tr:last-child td{border-bottom:0 !important}<br \/>}<br \/><\/style>\n<article class=\"mj-sheet\" style=\"background: #fbf9f5; border: 1px solid #e4dfd6; border-radius: 24px; overflow: hidden; box-shadow: 0 1px 0 rgba(28,35,40,.04),0 18px 40px -24px rgba(28,35,40,.18);\">\n<div class=\"mj-bar\" style=\"height: 4px; background: #2c5a52;\" data-rm-block-id=\"block-2\"><\/div>\n<div class=\"mj-sheet-inner\" style=\"padding: 32px 36px 28px;\">\n<div class=\"mj-kicker\" style=\"display: flex; align-items: center; justify-content: center; flex-wrap: wrap; gap: 8px; margin: 0 0 18px; color: #2c5a52; font-size: 11px; font-weight: 600; letter-spacing: .18em; text-align: center;\" data-rm-block-id=\"block-3\">Direct Shipping from Overseas (Direct Shipping from Japan)<\/div>\n<h2 class=\"mj-title\" style=\"font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 24px; font-weight: bold; line-height: 1.4; text-align: center; margin: 0 0 12px; color: #1c2328;\" data-rm-block-id=\"block-4\">Manjaro Subcutaneous Injection of Ateos<\/h2>\n<h2 class=\"mj-title\" style=\"font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 24px; font-weight: bold; line-height: 1.4; text-align: center; margin: 0 0 12px; color: #1c2328;\" data-rm-block-id=\"block-5\">Tixipentide Weight-Loss Injection<\/h2>\n<h2 class=\"mj-title\" style=\"font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 24px; font-weight: bold; line-height: 1.4; text-align: center; margin: 0 0 12px; color: #1c2328;\" data-rm-block-id=\"block-6\"><span style=\"font-size: 16px;\">Mounjaro\u00ae Subcutaneous Injection ATEOS\u00ae<\/span><br \/>\n<span style=\"font-size: 15px; font-weight: 600;\">2.5 mg \/ 5 mg \/ 7.5 mg \/ 10 mg \/ 12.5 mg \/ 15 mg<\/span><\/h2>\n<p class=\"mj-keys\" style=\"margin: 0 auto 10px; max-width: 620px; text-align: center; color: #3f4a46; font-size: 14px; font-weight: 600; line-height: 1.7;\" data-rm-block-id=\"block-7\">Document Number 2499422G1024_1_11 | Company Code 530471<br \/>\nRevised in May 2026 (10th Edition) \/ Revised in September 2026 (11th Edition)<\/p>\n<p class=\"mj-keys\" style=\"margin: 0 auto 18px; max-width: 620px; text-align: center; color: #2c5a52; font-size: 14px; font-weight: 600; line-height: 1.7;\" data-rm-block-id=\"block-8\">Long-acting GIP\/GLP-1 receptor agonists | Chilzepatide Injection | Type 2 Diabetes<\/p>\n<figure class=\"mj-figure\" style=\"margin: 0 auto 24px; max-width: 100%; background: #fffcf8; border: 1px solid #e4dfd6; border-radius: 20px; padding: 12px;\" data-rm-block-id=\"block-9\"><a href=\"https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/08\/1-21.webp\"><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-7007 size-full aligncenter\" style=\"width: 100%; height: auto; display: block;\" src=\"https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/08\/1-21.webp\" alt=\"Mounjaro Weight-Loss Injection\" width=\"500\" height=\"500\" \/><\/a><\/figure>\n<p style=\"font-size: 16px; font-weight: bold; color: #1c2328; margin: 0 0 12px; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif;\" data-rm-block-id=\"block-10\">Product Details \/ Acknowledgments, etc.<\/p>\n<div class=\"mj-specs-wrap\" style=\"margin: 0 0 28px; border: 1px solid #e4dfd6; border-radius: 16px; background: #fffcf8;\">\n<table class=\"mj-specs\" style=\"height: 1087px;\" width=\"652\">\n<tbody>\n<tr>\n<th style=\"text-align: center;\" data-rm-block-id=\"block-11\">Japanese Standard Product Classification Code<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-12\">872499<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: center;\" data-rm-block-id=\"block-13\">Pharmacological Classification Name<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-14\">Long-acting GIP\/GLP-1 receptor agonists<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: center;\" data-rm-block-id=\"block-15\">Generic Name<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-16\">Tirzepatide Injection (Tirzepatide)<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-17\">2.5mg<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-18\">Manjaro Subcutaneous Injection 2.5 mg Ateos<br \/>\nYJ 2499422G1024<br \/>\nApproved 30400AMX00420<br \/>\nSales Begin April 2023<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-19\">5mg<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-20\">Manjaro Subcutaneous Injection 5 mg, Ateos<br \/>\nYJ 2499422G2020<br \/>\nApproved 30400AMX00421<br \/>\nSales Begin April 2023<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-21\">7.5mg<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-22\">Manjaro Subcutaneous Injection 7.5 mg Ateos<br \/>\nYJ 2499422G3027<br \/>\nApproved 30400AMX00422<br \/>\nSales Begin June 2023<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-23\">10mg<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-24\">Manjaro Subcutaneous Injection 10 mg Ateos<br \/>\nYJ 2499422G4023<br \/>\nApproved 30400AMX00423<br \/>\nSales Begin June 2023<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-25\">12.5mg<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-26\">Manjaro Subcutaneous Injection 12.5 mg Ateos<br \/>\nYJ 2499422G5020<br \/>\nApproved 30400AMX00424<br \/>\nSales Begin June 2023<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-27\">15mg<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-28\">Manjaro Subcutaneous Injection 15 mg Ateos<br \/>\nYJ 2499422G6026<br \/>\nApproved 30400AMX00425<br \/>\nSales Begin June 2023<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-29\">Storage Instructions \/ Expiration Date<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-30\">Store at 2\u20138\u00b0C \/ 24 months<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-31\">Regulatory Distinctions<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-32\">\u2013<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-33\">Manufacturing and Selling Yuan<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-34\">Eli Lilly Japan K.K.<br \/>\n5-1-28 Isogami-dori, Chuo Ward, Kobe City<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-35\">Sales Yuan<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-36\">Tanabe Pharma Co., Ltd.<br \/>\n3-2-10 Doshomachi, Chuo Ward, Osaka City<\/td>\n<\/tr>\n<tr>\n<th data-rm-block-id=\"block-37\">Packaging<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-38\">Various sizes: 0.5 mL \u00d7 2 sets<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: center;\" data-rm-block-id=\"block-39\">Mailing method<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-40\">Direct Shipping from Overseas (Direct Shipping from Japan)<\/td>\n<\/tr>\n<tr>\n<th style=\"text-align: center;\" data-rm-block-id=\"block-41\">Order Fulfillment and Shipping Times<\/th>\n<td style=\"text-align: center;\" data-rm-block-id=\"block-42\">After confirming payment and prescription eligibility,<br \/>\nOrders are typically shipped within 4 to 7 business days.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #2c5a52; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #1c2328;\" data-rm-block-id=\"block-43\">1. Product hint<\/h3>\n<div class=\"mj-panel\" style=\"background: #f3efe8; border: 1px solid #e4dfd6; border-radius: 14px; padding: 16px 18px; color: #5e6560; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-44\">Conditions for Approval: A drug risk management plan must be developed and properly implemented.<\/p>\n<p style=\"margin: 0;\" data-rm-block-id=\"block-45\">Handling Instructions: Avoid freezing; store at 2\u20138\u00b0C in the dark. Do not use if frozen. When storing at room temperature, keep the product in its outer packaging at a temperature not exceeding 37\u00b0C and use within 21 days.<\/p>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #2c5a52; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #1c2328;\" data-rm-block-id=\"block-46\">2. Product Characteristics and Mechanism of Action (18.)<\/h3>\n<div class=\"mj-panel\" style=\"background: #f3efe8; border: 1px solid #e4dfd6; border-radius: 14px; padding: 16px 18px; color: #5e6560; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-47\">This product is an agonist of both the GIP receptor and the GLP-1 receptor; it binds to and activates both receptors, promoting insulin secretion in a glucose-concentration-dependent manner. It is a 39-amino acid peptide containing a C20 fatty acid side chain that binds to endogenous albumin, thereby prolonging its half-life and ensuring sustained action.<\/p>\n<p style=\"margin: 0;\" data-rm-block-id=\"block-48\">Pharmacological Effects (based on administration of more than 15 mg once weekly for 28 weeks, including an evaluation after titration to steady state): Reduces fasting and postprandial blood glucose levels; promotes phase 1 and phase 2 insulin secretion in response to glucose; reduces fasting and postprandial glucagon levels; increases systemic insulin sensitivity (M value); delays gastric emptying (as indicated by acetaminophen Cmax and AUC; most pronounced after the first dose, diminishing after 4 weeks of repeated administration).<\/p>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #2c5a52; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #1c2328;\" data-rm-block-id=\"block-49\">3. Specifications and Properties (3.2)<\/h3>\n<div class=\"mj-panel\" style=\"background: #f3efe8; border: 1px solid #e4dfd6; border-radius: 14px; padding: 16px 18px; color: #5e6560; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0;\" data-rm-block-id=\"block-50\">All strengths are for injection: a colorless to pale yellow to pale brown, clear or slightly milky liquid. Strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg (Ateos pre-filled kits, 0.5 mL \u00d7 2 kits each).<\/p>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #2c5a52; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #1c2328;\" data-rm-block-id=\"block-51\">4. Ingredient Information (3.1\/19.)<\/h3>\n<div class=\"mj-panel\" style=\"background: #f3efe8; border: 1px solid #e4dfd6; border-radius: 14px; padding: 16px 18px; color: #5e6560; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-52\"><strong style=\"color: #1c2328;\">3.1 Composition<\/strong>\u3000Chilizepatide in a single package: 2.5, 5, 7.5, 10, 12.5, and 15 mg.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-53\">Excipients (same for all strengths): disodium hydrogen phosphate heptahydrate 0.7 mg, sodium chloride 4.1 mg, hydrochloric acid q.s., sodium hydroxide q.s.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-54\"><strong style=\"color: #1c2328;\">19.<\/strong> Generic Name: Tirzepatide (Tirzepatide) [JAN] Molecular Formula: C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub>\u3000Molecular weight: 4813.45 Appearance: white powder.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-55\">Residues 2 and 13 are 2-methyl-Ala, and the C-terminus is an amidated Ser; 1,20-docosadienoic acid is linked to Lys at position 20 via Glu and two 8-amino-3,6-dioxooctanoic acid linkers. A synthetic peptide consisting of 39 amino acid residues.<\/p>\n<p data-rm-block-id=\"block-56\"><img decoding=\"async\" src=\"https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/09\/530471_2499422G1024_1_11_fig03.gif\" alt=\"Structural Formula\" \/><\/p>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #2c5a52; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #1c2328;\" data-rm-block-id=\"block-57\">5. Indications and Usage (4.\/5.)<\/h3>\n<div class=\"mj-panel\" style=\"background: #f3efe8; border: 1px solid #e4dfd6; border-radius: 14px; padding: 16px 18px; color: #5e6560; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-58\"><strong style=\"color: #1c2328;\">4. Efficacy or Effectiveness<\/strong>\u3000Type 2 Diabetes<\/p>\n<p style=\"margin: 0;\" data-rm-block-id=\"block-59\">5. This treatment should be considered only when the basic dietary and exercise therapies for diabetes have been fully implemented but have not yielded sufficient results.<\/p>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #2c5a52; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #1c2328;\" data-rm-block-id=\"block-60\">6. Dosage and Administration (6.\/7.)<\/h3>\n<div class=\"mj-panel\" style=\"background: #f3efe8; border: 1px solid #e4dfd6; border-radius: 14px; padding: 16px 18px; color: #5e6560; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-61\">For adults, the usual maintenance dose of chizepatide is 5 mg administered subcutaneously once weekly. However, treatment should begin with 2.5 mg once weekly, and the dose should be increased to 5 mg once weekly after 4 weeks.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-62\">The dose may be adjusted as appropriate based on the patient's condition; if a 5 mg dose once weekly is insufficient, the dose may be increased by 2.5 mg at intervals of at least 4 weeks. The maximum dose is 15 mg once weekly.<\/p>\n<ol style=\"margin: 0; padding-left: 20px;\">\n<li style=\"margin-bottom: 6px;\" data-rm-block-id=\"block-63\">7.1 Once a week; the vote must be cast on the same day of the week each week.<\/li>\n<li style=\"margin-bottom: 6px;\" data-rm-block-id=\"block-64\">7.2 Missed Dose: If there are still 3 days (72 hours) or more until the next scheduled dose, administer the missed dose immediately; thereafter, continue with the original schedule. If there are less than 3 days remaining, skip this dose and wait until the originally scheduled date. When rescheduling to a different day of the week, ensure there is an interval of at least 3 days (72 hours) since the previous dose.<\/li>\n<li style=\"margin-bottom: 6px;\" data-rm-block-id=\"block-65\">7.3 If the patient cannot tolerate the medication due to gastrointestinal disturbances, consider reducing the dose or delaying the dose escalation.<\/li>\n<li data-rm-block-id=\"block-66\">7.4 Dose-dependent weight loss has been observed. When increasing the dose, in addition to monitoring blood glucose control, attention must be paid to weight loss, and the decision to increase the dose should be made with caution.<\/li>\n<\/ol>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h mj-h-alert\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #7a2e2e; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #7a2e2e;\" data-rm-block-id=\"block-67\">7. Important Notes (8.\/9.\/10.\/11.\/20.)<\/h3>\n<div class=\"mj-panel mj-panel-alert\" style=\"background: #f7efe9; border: 1px solid #e4cfc6; border-radius: 14px; padding: 16px 18px; color: #6b3a34; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-68\"><strong style=\"color: #7a2e2e;\">8. Important Basic Precautions<\/strong><\/p>\n<ol style=\"margin: 0 0 12px; padding-left: 20px;\">\n<li data-rm-block-id=\"block-69\">8.1 This product is not an insulin substitute. Confirm insulin dependence prior to administration. There have been reports of acute hyperglycemia and diabetic ketoacidosis following a switch from insulin to a GLP-1 receptor agonist.<\/li>\n<li data-rm-block-id=\"block-70\">8.2 Monitor blood glucose and urine glucose levels regularly to assess effectiveness; if the treatment is not effective after 3 to 4 months, consider switching to a more appropriate treatment.<\/li>\n<li data-rm-block-id=\"block-71\">8.3 Long-acting formulations may continue to have an effect after discontinuation; therefore, attention must be paid to blood glucose fluctuations as well as the prevention and management of side effects.<\/li>\n<li data-rm-block-id=\"block-72\">8.4 Patients must be fully informed about the symptoms of hypoglycemia and how to manage them.<\/li>\n<li data-rm-block-id=\"block-73\">8.5 May cause hypoglycemia; exercise caution when working at heights, driving, or engaging in similar activities.<\/li>\n<li data-rm-block-id=\"block-74\">Common precautions for other similar formulations: acute pancreatitis, gastrointestinal disorders \/ dehydration\/acute kidney injury, thyroid disorders, biliary tract disorders, hypotension, self-injection training and disposal, diabetic retinopathy; must not be used in combination with other chirzepride formulations (such as Zepbound) or other GLP-1 receptor agonists; efficacy and safety when used in combination with DPP-4 inhibitors have not been established.<\/li>\n<\/ol>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-75\"><strong style=\"color: #7a2e2e;\">9.<\/strong> Severe gastrointestinal disorders, history of pancreatitis, predisposition to hypoglycemia, severe diabetic retinopathy, abdominal surgery\/ history of intestinal obstruction, risk of aspiration under general anesthesia or deep sedation, women of childbearing potential must use contraception during treatment and for 1 month after the final dose, not to be administered to pregnant women, use during breastfeeding requires careful consideration, not tested in children, use with caution in the elderly.<\/p>\n<p style=\"margin: 0 0 6px;\" data-rm-block-id=\"block-76\"><strong style=\"color: #7a2e2e;\">10.2 Precautions for Concomitant Use<\/strong>\u3000Diabetes medications (increased risk of hypoglycemia, especially sulfonylureas, rapid-acting insulin secretagogues, and insulin; consider reducing the dose); Oral contraceptives (effectiveness may be reduced during initiation or the initial dose-escalation phase; delayed gastric emptying); narrow-therapeutic-index oral medications such as warfarin (delayed Tmax; monitoring required).<\/p>\n<p style=\"margin: 8px 0 6px;\" data-rm-block-id=\"block-77\"><strong style=\"color: #7a2e2e;\">11.1 Serious Adverse Effects<\/strong>\u3000Hypoglycemia (frequency unknown); acute pancreatitis (less than 0.11 TP3T); cholecystitis (frequency unknown), cholangitis (less than 0.11 TP3T), cholestatic jaundice (frequency unknown); Allergic reactions, angioedema (frequency unknown); ileus (frequency unknown). Common: Nausea, diarrhea, loss of appetite, etc.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-78\"><strong>20.<\/strong> To prevent freezing, store at 2\u20138\u00b0C away from light; do not use if frozen. Store in the outer carton at room temperature not exceeding 30\u00b0C and use within 21 days.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-79\">Plasma concentrations in Japanese patients with type 2 diabetes (Week 32):<\/p>\n<p data-rm-block-id=\"block-80\"><img decoding=\"async\" src=\"https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/09\/530471_2499422G1024_1_11_fig01.gif\" alt=\"Plasma concentration\" \/><\/p>\n<p style=\"margin: 12px 0 8px;\" data-rm-block-id=\"block-81\">Cumulative incidence of major cardiovascular events (compared with dulaglutide):<\/p>\n<p data-rm-block-id=\"block-82\"><img decoding=\"async\" src=\"https:\/\/hkeemall.com\/wp-content\/uploads\/2026\/09\/530471_2499422G1024_1_11_fig02.gif\" alt=\"Cumulative Incidence of MACE\" \/><\/p>\n<p style=\"margin: 8px 0 0; font-size: 13px;\" data-rm-block-id=\"block-83\">In the cardiovascular outcomes trial, the change in HbA1c at Week 144 was: this drug, \u22121.80 \u00b1 1.37 (5,530 patients); dulaglutide, \u22120.93 \u00b1 1.36 (5,390 patients). The incidence of severe hypoglycemia was approximately 0.71 TP3T in both groups. Major adverse effects in the study drug group included nausea (23.31 TP3T), diarrhea (19.61 TP3T), and decreased appetite (16.01 TP3T).<\/p>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 10px;\">\n<h3 class=\"mj-h mj-h-alert\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #7a2e2e; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #7a2e2e;\" data-rm-block-id=\"block-84\">8. Contraindications (2.)<\/h3>\n<div class=\"mj-panel mj-panel-alert\" style=\"background: #f7efe9; border: 1px solid #e4cfc6; border-radius: 14px; padding: 16px 18px; color: #6b3a34; font-size: 14px; line-height: 1.8;\">\n<ol style=\"margin: 0 0 12px; padding-left: 20px;\">\n<li style=\"margin-bottom: 6px;\" data-rm-block-id=\"block-85\">2.1 Patients with a history of allergy to any of the ingredients in this product<\/li>\n<li style=\"margin-bottom: 6px;\" data-rm-block-id=\"block-86\">2.2 Diabetic ketoacidosis, diabetic coma or precoma, patients with type 1 diabetes [must be treated promptly with insulin; this product should not be administered.]<\/li>\n<li data-rm-block-id=\"block-87\">2.3 Emergencies such as severe infections or surgery [Blood glucose should be managed with insulin preparations; this product is not suitable for use in these situations.]<\/li>\n<\/ol>\n<p style=\"margin: 0;\" data-rm-block-id=\"block-88\">This product must not be administered to pregnant women or women who may be pregnant. This product is a highly potent, prescription-only medication and must be used only as prescribed by a physician. Please refer to the original Japanese package insert for details.<\/p>\n<\/div>\n<\/section>\n<section class=\"mj-sec\" style=\"margin: 0 0 22px;\">\n<h3 class=\"mj-h\" style=\"margin: 0 0 10px; padding: 0 0 8px; border-bottom: 1.5px solid #2c5a52; font-family: 'Noto Serif JP','Songti TC','PMingLiU',serif; font-size: 17px; font-weight: bold; color: #1c2328;\" data-rm-block-id=\"block-89\">21\u201326. Other Official Information<\/h3>\n<div class=\"mj-panel\" style=\"background: #f3efe8; border: 1px solid #e4dfd6; border-radius: 14px; padding: 16px 18px; color: #5e6560; font-size: 14px; line-height: 1.8;\">\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-90\"><strong style=\"color: #1c2328;\">21.<\/strong> A drug risk management plan must be developed and implemented.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-91\"><strong style=\"color: #1c2328;\">22.<\/strong> 2.5\/5\/7.5\/10\/12.5\/15 mg Ateos, 0.5 mL each \u00d7 2 sets.<\/p>\n<p style=\"margin: 0 0 8px;\" data-rm-block-id=\"block-92\"><strong style=\"color: #1c2328;\">24.<\/strong> Eli Lilly Japan K.K. Medical Information Inquiries TEL: 0120-360-605 medical.lilly.com\/jp<br \/>\nTanabe Pharma Co., Ltd. Medication Consultation Center TEL: 0120-753-280<\/p>\n<p style=\"margin: 0;\" data-rm-block-id=\"block-93\"><strong style=\"color: #1c2328;\">26.<\/strong> Manufacturer: Eli Lilly Japan K.K. \/ Distributor: Tanabe Pharma Co., Ltd. \u00ae: Registered trademark<\/p>\n<\/div>\n<\/section>\n<div class=\"mj-foot\" style=\"margin: 8px 0 0; padding: 18px 8px 4px; border-top: 1px solid #e4dfd6; text-align: center; color: #7a2e2e; font-size: 13px; line-height: 1.7;\" data-rm-block-id=\"block-94\">\u203b This page was translated by JINZE based on PMDA Package Insert 2499422G1024_1_11. It is not a substitute for a physician\u2019s prescription or the original Japanese version.<br \/>\n<a style=\"color: #7a2e2e; font-weight: bold; text-decoration: underline;\" href=\"https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/530471_2499422G1024_1_11#HDR_ContraIndications\" target=\"_blank\" rel=\"noreferrer noopener\">Enter \"Manjaro\" in the \"Package Insert Information\" field on the PMDA website to search for the original version.<\/a><\/div>\n<\/div>\n<\/article>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>International Direct Shipping (Direct from Japan) Mounjaro\u00ae Subcutaneous Injections (Ateos), a substitute for exenatide, weight-loss injections<\/p>\n<div class=\"klb-readmore post-buttons\"><a class=\"button rounded primary\" href=\"https:\/\/zepbound-japan.com\/en\/product\/1793347459\/\">Read More <i class=\"klbth-icon-right-arrow\"><\/i><\/a><\/div>","protected":false},"featured_media":8468,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[36],"product_tag":[],"class_list":["post-8467","product","type-product","status-publish","has-post-thumbnail","product_cat-health","first","instock","shipping-taxable","purchasable","product-type-variable"],"_links":{"self":[{"href":"https:\/\/zepbound-japan.com\/en\/wp-json\/wp\/v2\/product\/8467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zepbound-japan.com\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/zepbound-japan.com\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/zepbound-japan.com\/en\/wp-json\/wp\/v2\/comments?post=8467"}],"version-history":[{"count":5,"href":"https:\/\/zepbound-japan.com\/en\/wp-json\/wp\/v2\/product\/8467\/revisions"}],"predecessor-version":[{"id":8487,"href":"https:\/\/zepbound-japan.com\/en\/wp-json\/wp\/v2\/product\/8467\/revisions\/8487"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/zepbound-japan.com\/en\/wp-json\/wp\/v2\/media\/8468"}],"wp:attachment":[{"href":"https:\/\/zepbound-japan.com\/en\/wp-json\/wp\/v2\/media?parent=8467"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/zepbound-japan.com\/en\/wp-json\/wp\/v2\/product_brand?post=8467"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/zepbound-japan.com\/en\/wp-json\/wp\/v2\/product_cat?post=8467"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/zepbound-japan.com\/en\/wp-json\/wp\/v2\/product_tag?post=8467"}],"curies":[{"name":"Well played","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}